Amgen: Jefferies says 'buy' - optimistic about share
(CercleFinance.com) - On Thursday an analyst at Jefferies confirms his "buy" recommendation on the Amgen share, appreciating a "expansion now from 3 new blockbusters pot'l coming over next few years" and a "significantly improving earnings profile over next 3-5 years.
"
Detecting several catalysts for ongoing studies, the broker confirms its target price of 235 dollars, against a current share price of around 204 dollars.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"
Detecting several catalysts for ongoing studies, the broker confirms its target price of 235 dollars, against a current share price of around 204 dollars.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.